Top Markets
Coin of the day
SQZ Biotechnologies Company SQZ Biotechnologies Company

SQZ Biotechnologies Company

SQZ
株式のランク #38920
SQZ Biotechnologies, a biotechnology firm currently in the clinical development... SQZ Biotechnologies, a biotechnology firm currently in the clinical development phase, is focused on creating cell-based therapies for various severe ailments, including cancerous growths, autoimmune disorders, and infectious diseases. Its primary experimental therapeutic, known as SQZ-PBMC-HPV, is derived from its SQZ Antigen Presenting Cells technology. This treatment is currently undergoing Phase I clinical trials, both as a standalone therapy and alongside other immune-oncology treatments, to address advanced or metastatic solid tumors positive for HPV16, encompassing cancers of the cervix, head-and-neck, anus, penis, vulva, and vagina. Furthermore, the company is progressing with SQZ-AAC-HPV, another Phase I clinical candidate targeting the same HPV16+ advanced or metastatic solid tumors, which is also being evaluated as a single agent and in conjunction with other immune-modulating agents. Beyond these, SQZ Biotechnologies is also advancing its SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers platforms. Established in 2013, the company operates from its main office in Watertown, Massachusetts.
株価
$0.05083
最終同期: 2023-09-01
時価総額
$732.57K
変化(1日)
8.15%
変化(1年)
0.00%
US
取引 SQZ Biotechnologies Company (SQZ)

カテゴリー

SQZ Biotechnologies Company(SQZ)の配当利回りの履歴
SQZ Biotechnologies Company(銘柄コード: SQZ)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
SQZ Biotechnologies Company(SQZ)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)